Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.

[1]  R. Advani,et al.  A phase I trial of liposomal doxorubicin, paclitaxel and valspodar (PSC-833), an inhibitor of multidrug resistance. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  P. Sonneveld,et al.  The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. , 2005, Blood.

[3]  H. McLeod,et al.  Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar , 2005, British Journal of Cancer.

[4]  N. Baldini,et al.  Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma. , 2004, Oncology reports.

[5]  M. Caligiuri,et al.  Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Advani,et al.  Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Robert,et al.  Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance , 2004, Cancer Chemotherapy and Pharmacology.

[8]  M. J. García,et al.  Immunosuppressive Therapy for Paediatric Transplant Patients , 2002, Clinical pharmacokinetics.

[9]  F. Appelbaum,et al.  A phase I study of induction chemotherapy for older patients with newly diagnosed acute myeloid leukemia (AML) using mitoxantrone, etoposide, and the MDR modulator PSC 833: a southwest oncology group study 9617. , 2000, Leukemia research.

[10]  C. R. Pinkerton,et al.  Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines , 2000, British Journal of Cancer.

[11]  P. Westervelt,et al.  Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Zalcberg,et al.  Induction of MDR1 gene expression by anthracycline analogues in a human drug resistant leukaemia cell line , 1999, British Journal of Cancer.

[13]  A. Boddy,et al.  High-dose cyclosporin with etoposide--toxicity and pharmacokinetic interaction in children with solid tumours. , 1998, British Journal of Cancer.

[14]  C. R. Pinkerton,et al.  Multidrug resistance modulation in rhabdomyosarcoma and neuroblastoma cell lines. , 1998, International journal of oncology.

[15]  G. Giaccone,et al.  A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[16]  E. Estey,et al.  Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. R. Pinkerton,et al.  Multidrug resistance reversal in childhood malignancies--potential for a real step forward? , 1996, European journal of cancer.

[18]  N. Bleehen,et al.  Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Mark L. Greenberg,et al.  Anaphylactoid reactions in children receiving high-dose intravenous cyclosporine for reversal of tumor resistance: the causative role of improper dissolution of Cremophor EL. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Cowman,et al.  Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line. , 1995, British Journal of Cancer.

[21]  C. R. Pinkerton,et al.  Phase II study of rapid-scheduled etoposide in paediatric soft tissue sarcomas. , 1995, European journal of cancer.

[22]  C. R. Pinkerton,et al.  Enhanced toxicity of dactinomycin and vincristine by cyclosporine given to reverse multidrug resistance. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Laissue,et al.  Pharmacologic interactions between the resistance‐modifying cyclosporine sdz psc 833 and etoposide (VP 16–213) enhance In Vivo cytostatic activity and toxicity , 1992, International journal of cancer.

[24]  C. R. Pinkerton,et al.  Pilot study of a rapid etoposide-cisplatin regimen in paediatric soft tissue sarcomas. , 1992, European journal of cancer.

[25]  M. Cairo,et al.  Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. , 1989, Cancer research.

[26]  M C Willingham,et al.  Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. , 1987, Proceedings of the National Academy of Sciences of the United States of America.